304 related articles for article (PubMed ID: 25015035)
1. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.
De P; Carlson J; Leyland-Jones B; Dey N
Oncotarget; 2014 Jul; 5(13):4581-602. PubMed ID: 25015035
[TBL] [Abstract][Full Text] [Related]
2. CIP2A inhibits PP2A in human malignancies.
Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
[TBL] [Abstract][Full Text] [Related]
4. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
Fujiki H; Sueoka E; Watanabe T; Suganuma M
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
[TBL] [Abstract][Full Text] [Related]
5. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
6. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
7. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells.
Liu X; Duan C; Ji J; Zhang T; Yuan X; Zhang Y; Ma W; Yang J; Yang L; Jiang Z; Yu H; Liu Y
Oncol Rep; 2017 Jul; 38(1):271-278. PubMed ID: 28534965
[TBL] [Abstract][Full Text] [Related]
8. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Khanna A; Pimanda JE; Westermarck J
Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
[TBL] [Abstract][Full Text] [Related]
9. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
Pallai R; Bhaskar A; Sodi V; Rice LM
Transcription; 2012; 3(6):323-35. PubMed ID: 23117818
[TBL] [Abstract][Full Text] [Related]
10. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
[TBL] [Abstract][Full Text] [Related]
11. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
[TBL] [Abstract][Full Text] [Related]
12. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
[TBL] [Abstract][Full Text] [Related]
14. Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.
Birkman EM; Elzagheid A; Jokilehto T; Avoranta T; Korkeila E; Kulmala J; Syrjänen K; Westermarck J; Sundström J
Cancer Med; 2018 Mar; 7(3):698-706. PubMed ID: 29441695
[TBL] [Abstract][Full Text] [Related]
15. The role of CIP2A in cancer: A review and update.
Soofiyani SR; Hejazi MS; Baradaran B
Biomed Pharmacother; 2017 Dec; 96():626-633. PubMed ID: 29035828
[TBL] [Abstract][Full Text] [Related]
16. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.
Pallai R; Bhaskar A; Barnett-Bernodat N; Gallo-Ebert C; Pusey M; Nickels JT; Rice LM
Tumour Biol; 2015 Aug; 36(8):6383-90. PubMed ID: 25833693
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
Cai F; Zhang L; Xiao X; Duan C; Huang Q; Fan C; Li J; Liu X; Li S; Liu Y
Oncol Rep; 2016 Aug; 36(2):1180-6. PubMed ID: 27350399
[TBL] [Abstract][Full Text] [Related]
19. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
